Home・Elenco Azioni・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Chiusa

SettoreSettore sanitario

207.75 -2.66

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

206.19

Massimo

213.31

Metriche Chiave
By Trading Economics
Entrata	13M -51M
Vendite	27M 218M
EPS	-0.99
Margine di Profitto	-23.498
Dipendenti	1,346
EBITDA	11M -50M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+35.8% upside

Dividendi
By Acuity
Utili prossimi	2 nov 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	485M 11B
Apertura precedente	210.41
Chiusura precedente	207.75

Notizie sul Sentiment di mercato

By Acuity

93%

2 / 339 Classifica in Healthcare

Axsome Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

18 set 2026, 19:46 UTC

Axsome Therapeutics Inc shares fell after reaching an early high, remaining below Thursday's close and stabilizing around the middle of its one-month trading range.

16 set 2026, 20:10 UTC

Macro Event

Axsome Therapeutics Inc is advancing amid broader market reactions to the Federal Reserve's 25 basis point interest rate hike, consolidating gains above its 20-day moving average.

15 set 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, showing unusual volatility and trading below its 20-day moving average. No specific news was identified.

14 set 2026, 20:07 UTC

Social Media

Axsome Therapeutics shares are lower today, continuing a decline since Friday. Recent prescription data and a price target of $316 from Mizuho have not supported the stock.

12 set 2026, 00:01 UTC

Social Media

Axsome Therapeutics shares rise in after-market trading, supported by Mizuho's $316 price target and positive prescription data for Auvelity.

11 set 2026, 20:01 UTC

News

Social Media

Axsome Therapeutics shares rise following positive analyst commentary on Auvelity's launch and strong prescription growth, with unusually high trading volume today.

9 set 2026, 20:07 UTC

Axsome Therapeutics Inc. shares are higher today, continuing a positive trend since Tuesday's close amid typical trading activity within its one-month range.

8 set 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today amid routine trading, with no specific company news identified. The stock has gained since Friday's close.

4 set 2026, 22:40 UTC

Axsome Therapeutics Inc. shares are higher in after-market hours, recovering from an earlier pullback and achieving a notable return since Friday's close.

3 set 2026, 20:07 UTC

Axsome Therapeutics Inc shares are trading lower today, with no specific news identified to explain the decline amid a broader market downturn.

2 set 2026, 20:01 UTC

News

Axsome Therapeutics will participate in several upcoming investor conferences, boosting shares amid positive sentiment regarding its outreach efforts.

1 set 2026, 19:51 UTC

Event

News

Axsome Therapeutics Inc. announced the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation, boosting shares higher.

31 ago 2026, 21:02 UTC

Event

Axsome Therapeutics shares rise in after-market hours following the dosing of the first patient in the SUMMIT Phase 3 trial for AXS-05.

29 ago 2026, 00:01 UTC

Axsome Therapeutics Inc is higher in after-market trading, advancing since Friday's close, though still below its 20-day moving average.

28 ago 2026, 23:46 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. They remain below their 20-day moving average.

27 ago 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading lower, continuing a decline since Wednesday and remaining near the lower end of their one-month trading range.

26 ago 2026, 19:36 UTC

Axsome Therapeutics Inc. shares are trading higher today, recovering from an early dip. The stock remains below its 20-day moving average.

25 ago 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing down and trading below the 20-day moving average.

24 ago 2026, 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading. The stock has declined for four consecutive sessions and remains below its 20-day moving average.

21 ago 2026, 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20 ago 2026, 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17 ago 2026, 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14 ago 2026, 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13 ago 2026, 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12 ago 2026, 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11 ago 2026, 19:45 UTC

Social Media

News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10 ago 2026, 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7 ago 2026, 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6 ago 2026, 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5 ago 2026, 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

Confronto tra pari

Modifica del prezzo

Axsome Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

35.8% in crescita

Previsioni per 12 mesi

Media 291 USD 35.8%

Alto 380 USD

Basso 251 USD

Basato su 13 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Axsome Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

13 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 13 che hanno fornito valutazioni azionarie a Axsome Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

2 / 339 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.